Schoenberg Mark's Form 4/A amendment
AmendedUroGen Pharma Ltd. (URGN) · filed Feb 5, 2024
- Accession no.
- 0001437749-24-003153
- Filed
- Feb 5, 2024
- Trade date
- Feb 1, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Feb 2, 2024
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $59.8K. It was filed 4 days after the trade.
This amendment replaces 0001437749-24-003016 (filed Feb 2, 2024).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schoenberg MarkCIK 0001763581 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 1, 2024 | Ordinary Shares | SSaleDisposed | −1,137 | $15.78 | −$17,941.86 | 149,423 | Direct | |
| Feb 1, 2024 | Ordinary Shares | SSaleDisposed | −758 | $15.78 | −$11,961.24 | 149,998 | Direct | |
| Feb 1, 2024 | Ordinary Shares | SSaleDisposed | −1,894 | $15.78 | −$29,887.32 | 151,437 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.